HLNCF
Price
$4.82
Change
+$0.13 (+2.77%)
Updated
Aug 15 closing price
Capitalization
43.62B
STEK
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Aug 15 closing price
Capitalization
3.66M
Interact to see
Advertisement

HLNCF vs STEK

Header iconHLNCF vs STEK Comparison
Open Charts HLNCF vs STEKBanner chart's image
HALEON
Price$4.82
Change+$0.13 (+2.77%)
Volume$5.58K
Capitalization43.62B
Stemtech
Price$0.03
Change-$0.00 (-0.00%)
Volume$5.88K
Capitalization3.66M
HLNCF vs STEK Comparison Chart in %
Loading...
HLNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HLNCF vs. STEK commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HLNCF is a Hold and STEK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (HLNCF: $4.82 vs. STEK: $0.03)
Brand notoriety: HLNCF and STEK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HLNCF: 34% vs. STEK: 4%
Market capitalization -- HLNCF: $43.62B vs. STEK: $3.66M
HLNCF [@Pharmaceuticals: Generic] is valued at $43.62B. STEK’s [@Pharmaceuticals: Generic] market capitalization is $3.66M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HLNCF’s FA Score shows that 1 FA rating(s) are green whileSTEK’s FA Score has 0 green FA rating(s).

  • HLNCF’s FA Score: 1 green, 4 red.
  • STEK’s FA Score: 0 green, 5 red.
According to our system of comparison, both HLNCF and STEK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HLNCF’s TA Score shows that 4 TA indicator(s) are bullish while STEK’s TA Score has 2 bullish TA indicator(s).

  • HLNCF’s TA Score: 4 bullish, 3 bearish.
  • STEK’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, HLNCF is a better buy in the short-term than STEK.

Price Growth

HLNCF (@Pharmaceuticals: Generic) experienced а +0.73% price change this week, while STEK (@Pharmaceuticals: Generic) price change was -6.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HLNCF($43.6B) has a higher market cap than STEK($3.66M). HLNCF YTD gains are higher at: 2.991 vs. STEK (-44.449). HLNCF has higher annual earnings (EBITDA): 2.71B vs. STEK (-3.06M). HLNCF has more cash in the bank: 676M vs. STEK (260K). STEK has less debt than HLNCF: STEK (4.07M) vs HLNCF (8.45B). HLNCF has higher revenues than STEK: HLNCF (11B) vs STEK (5.1M).
HLNCFSTEKHLNCF / STEK
Capitalization43.6B3.66M1,189,956%
EBITDA2.71B-3.06M-88,732%
Gain YTD2.991-44.449-7%
P/E Ratio21.25N/A-
Revenue11B5.1M215,602%
Total Cash676M260K260,000%
Total Debt8.45B4.07M207,970%
FUNDAMENTALS RATINGS
STEK: Fundamental Ratings
STEK
OUTLOOK RATING
1..100
82
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
99
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
93
SEASONALITY SCORE
1..100
30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
HLNCFSTEK
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
55%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
HLNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MYRG181.01-0.53
-0.29%
MYR Group
GAUZ6.12-0.02
-0.33%
Gauzy Ltd
NI41.95-0.60
-1.41%
NiSource
KZIA8.03-0.23
-2.84%
Kazia Therapeutics Limited
BLMN7.00-0.26
-3.58%
Bloomin' Brands

HLNCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, HLNCF has been loosely correlated with HLN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HLNCF jumps, then HLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLNCF
1D Price
Change %
HLNCF100%
+2.77%
HLN - HLNCF
49%
Loosely correlated
+0.09%
SGIOF - HLNCF
21%
Poorly correlated
+13.16%
STEK - HLNCF
11%
Poorly correlated
+0.55%
EAPIF - HLNCF
11%
Poorly correlated
N/A
ZTS - HLNCF
10%
Poorly correlated
+0.69%
More

STEK and

Correlation & Price change

A.I.dvisor tells us that STEK and CNADF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that STEK and CNADF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STEK
1D Price
Change %
STEK100%
+0.55%
CNADF - STEK
25%
Poorly correlated
N/A
BFRI - STEK
12%
Poorly correlated
-3.73%
HLNCF - STEK
11%
Poorly correlated
+2.77%
PLSH - STEK
8%
Poorly correlated
N/A
EAPIF - STEK
6%
Poorly correlated
N/A
More